La cadena de opciones muestra datos clave de las opciones de acciones de Anixa Biosciences a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Anixa Biosciences..

Anixa Biosciences (NASDAQ:ANIX) Bolsa, Cadena de Opciones

Anixa Biosciences

Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.

Anixa Biosciences Inc

Trading Ideas

DRCT

Direct Digital Shares Resume Trade Then Again Halted On Circuit Breaker To The Upside, Stock Now Up 256.4%

<p>Financial giants have made a conspicuous bearish move on Applied Optoelectronics. Our analysis of options history for Applied Optoelectronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>) revealed 21 unusual trades.</p>
<p>Delving into the details, we found 38% of traders were bullish, while 47% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $432,603, and 15 were calls, valued at $986,947.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $22.5 to $50.0 for Applied Optoelectronics during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Applied Optoelectronics's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Applied Optoelectronics's whale activity within a strike price range from $22.5 to $50.0 in the last 30 days. </p>
<h3>Applied Optoelectronics Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734969631_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AAOI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$17.5</td>
<td>$16.5</td>
<td>$17.4</td>
<td>$22.50</td>
<td>$132.2K</td>
<td>1.7K</td>
<td align="right">46</td>
</tr>
<tr>
<td>AAOI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$6.5</td>
<td>$6.2</td>
<td>$6.5</td>
<td>$35.00</td>
<td>$130.0K</td>
<td>2.8K</td>
<td align="right">205</td>
</tr>
<tr>
<td>AAOI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$5.7</td>
<td>$5.4</td>
<td>$5.62</td>
<td>$35.00</td>
<td>$113.3K</td>
<td>2</td>
<td align="right">447</td>
</tr>
<tr>
<td>AAOI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$6.7</td>
<td>$6.2</td>
<td>$6.5</td>
<td>$45.00</td>
<td>$97.5K</td>
<td>1.3K</td>
<td align="right">250</td>
</tr>
<tr>
<td>AAOI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$5.7</td>
<td>$5.5</td>
<td>$5.65</td>
<td>$35.00</td>
<td>$92.8K</td>
<td>2</td>
<td align="right">808</td>
</tr>
</tbody>
</table>
</p>
<h3>About Applied Optoelectronics</h3>
<p>Applied Optoelectronics Inc is a provider of fiber-optic networking products for the Internet data center, cable television, telecommunications and fiber-to-the-home end markets. The company focuses on designing and manufacturing a range of optical communication products from components, to subassemblies, and modules to complete turn-key equipment. Demand for Applied Optoelectronics is driven by bandwidth demand in end markets. Through direct sales personnel, and manufacturing teams in the United States, China, and Taiwan, the company coordinates with customers to determine product design, qualifications, and performance. The company derives maximum revenue from Taiwan.</p>
<p>In light of the recent options history for Applied Optoelectronics, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Where Is Applied Optoelectronics Standing Right Now?</h3>
<ul>
<li>With a trading volume of 1,020,369, the price of AAOI is down by -2.23%, reaching $36.98.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 59 days from now.</li>
</ul>
<h3>Expert Opinions on Applied Optoelectronics</h3>
<p>4 market experts have recently issued ratings for this stock, with a consensus target price of $34.25.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; In a cautious move, an analyst from Northland Capital Markets downgraded its rating to Outperform, setting a price target of $40.<br />
&#x2A; An analyst from Rosenblatt persists with their Buy rating on Applied Optoelectronics, maintaining a target price of $44.<br />
&#x2A; An analyst from B. Riley Securities has revised its rating downward to Sell, adjusting the price target to $14.<br />
&#x2A; An analyst from Raymond James persists with their Outperform rating on Applied Optoelectronics, maintaining a target price of $39. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Applied Optoelectronics, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Markets

AAOI

Applied Optoelectronics's Options Frenzy: What You Need to Know

<p>Financial giants have made a conspicuous bullish move on CrowdStrike Holdings. Our analysis of options history for CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) revealed 19 unusual trades.</p>
<p>Delving into the details, we found 52% of traders were bullish, while 31% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $776,760, and 13 were calls, valued at $1,132,509.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $90.0 and $390.0 for CrowdStrike Holdings, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for CrowdStrike Holdings's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of CrowdStrike Holdings's whale activity within a strike price range from $90.0 to $390.0 in the last 30 days. </p>
<h3>CrowdStrike Holdings Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734969626_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CRWD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/31/25</td>
<td>$5.35</td>
<td>$3.0</td>
<td>$3.05</td>
<td>$305.00</td>
<td>$518.5K</td>
<td>4</td>
<td>1.7K</td>
</tr>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$160.5</td>
<td>$157.55</td>
<td>$158.05</td>
<td>$250.00</td>
<td>$316.1K</td>
<td>62</td>
<td>20</td>
</tr>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$148.45</td>
<td>$144.05</td>
<td>$146.75</td>
<td>$270.00</td>
<td>$293.5K</td>
<td>45</td>
<td>20</td>
</tr>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$81.8</td>
<td>$79.85</td>
<td>$81.8</td>
<td>$340.00</td>
<td>$89.9K</td>
<td>491</td>
<td>11</td>
</tr>
<tr>
<td>CRWD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.36</td>
<td>$1.35</td>
<td>$1.36</td>
<td>$300.00</td>
<td>$85.1K</td>
<td>5.0K</td>
<td>635</td>
</tr>
</tbody>
</table>
</p>
<h3>About CrowdStrike Holdings</h3>
<p>CrowdStrike is a cloud-based cybersecurity company specializing in next-generation security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform that offers a proverbial single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The Texas-based firm was founded in 2011 and went public in 2019.</p>
<p>Having examined the options trading patterns of CrowdStrike Holdings, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>CrowdStrike Holdings's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 1,143,560, the CRWD's price is down by -1.04%, now at $358.51. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 71 days.</li>
</ul>
<h3>Expert Opinions on CrowdStrike Holdings</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $398.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from RBC Capital has decided to maintain their Outperform rating on CrowdStrike Holdings, which currently sits at a price target of $365.<br />
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Buy rating on CrowdStrike Holdings with a target price of $400.<br />
&#x2A; Consistent in their evaluation, an analyst from Evercore ISI Group keeps a Outperform rating on CrowdStrike Holdings with a target price of $400.<br />
&#x2A; Consistent in their evaluation, an analyst from Jefferies keeps a Buy rating on CrowdStrike Holdings with a target price of $450.<br />
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Overweight rating for CrowdStrike Holdings, targeting a price of $375. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest CrowdStrike Holdings options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


CRWD

Check Out What Whales Are Doing With CRWD

<p>Financial giants have made a conspicuous bearish move on Newmont. Our analysis of options history for Newmont (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>) revealed 17 unusual trades.</p>
<p>Delving into the details, we found 41% of traders were bullish, while 58% showed bearish tendencies. Out of all the trades we spotted, 10 were puts, with a value of $1,501,139, and 7 were calls, valued at $711,269.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $35.0 to $55.0 for Newmont over the last 3 months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Newmont stands at 2141.25, with a total volume reaching 3,328.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Newmont, situated within the strike price corridor from $35.0 to $55.0, throughout the last 30 days.</p>
<h3>Newmont Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734969621_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$17.3</td>
<td>$17.15</td>
<td>$17.25</td>
<td>$55.00</td>
<td>$391.5K</td>
<td>118</td>
<td align="right">228</td>
</tr>
<tr>
<td>NEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$17.5</td>
<td>$17.4</td>
<td>$17.5</td>
<td>$55.00</td>
<td>$322.0K</td>
<td>118</td>
<td align="right">436</td>
</tr>
<tr>
<td>NEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$6.0</td>
<td>$4.95</td>
<td>$6.0</td>
<td>$37.50</td>
<td>$300.6K</td>
<td>8.9K</td>
<td align="right">510</td>
</tr>
<tr>
<td>NEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$8.65</td>
<td>$8.55</td>
<td>$8.65</td>
<td>$45.00</td>
<td>$257.7K</td>
<td>4.8K</td>
<td align="right">302</td>
</tr>
<tr>
<td>NEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$6.35</td>
<td>$6.25</td>
<td>$6.35</td>
<td>$42.50</td>
<td>$173.3K</td>
<td>3.1K</td>
<td align="right">300</td>
</tr>
</tbody>
</table>
</p>
<h3>About Newmont</h3>
<p>Newmont is the world's largest gold miner. It bought Goldcorp in 2019, combined its Nevada mines in a joint venture with competitor Barrick later that year, and also purchased competitor Newcrest in November 2023. Its portfolio includes 17 wholly or majority owned mines and interests in two joint ventures in the Americas, Africa, Australia and Papua New Guinea. The company is expected to produce roughly 5.5 million ounces of gold in 2024 from its core mines and 6.8 million in total. It is likely to sell a number of its higher cost, smaller mines accounting for 20% of forecast sales in 2024. Newmont also produces material amounts of copper, silver, zinc, and lead as byproducts. It had about two decades of gold reserves along with significant byproduct reserves at the end of December 2023.</p>
<p>In light of the recent options history for Newmont, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Current Position of Newmont</h3>
<ul>
<li>Currently trading with a volume of 1,927,050, the NEM's price is down by -1.89%, now at $37.55. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 59 days.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Newmont options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


This Is What Whales Are Betting On Newmont

<p>Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has outperformed the market over the past 10 years by 28.92% on an annualized basis producing an average annual return of 39.92%. Currently, Tesla has a market capitalization of $1.37 trillion. </p>
<p><strong>Buying $1000 In TSLA:</strong> If an investor had bought $1000 of TSLA stock 10 years ago, it would be worth <strong>$28,316.31</strong> today based on a price of $425.27 for TSLA at the time of writing.</p>
<h3>Tesla's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734969609_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


News

TSLA

$1000 Invested In Tesla 10 Years Ago Would Be Worth This Much Today

Trident Acquisitions Corp Units (1 Ord & 1 War)

TDACU

Trading Halt: Halt status updated at 11:00:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

<p>Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.</p>
<ul>
<li>Loop Capital increased <strong>Microsoft Corporation</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) price target from $500 to $550. Loop Capital analyst Eric Beder maintained a Buy rating. Microsoft shares closed at $436.60 on Friday. See how other analysts view this stock.</li>
<li>Truist Securities cut the price target for <strong>Vertex Pharmaceuticals Incorporated</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) from $550 to $460. Truist Securities analyst Joon Lee maintained a Buy rating. Vertex Pharmaceuticals shares closed at $397.27 on Friday. See how other analysts view this stock.</li>
<li>Goldman Sachs lowered the price target for <strong>Lennar Corporation</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) from $190 to $162. Goldman Sachs analyst Susan Maklari maintained a Neutral rating. Lennar shares closed at $138.08 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Benchmark boosted the price target for <strong>Humacyte, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) from $15 to $17. Benchmark analyst Bruce Jackson maintained a Buy rating. Humacyte shares closed at $4.64 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital <strong>Snowflake Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) price target from $185 to $205. Loop Capital analyst Mark Schappel maintained a Buy rating. Snowflake shares settled at $166.29 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>RBC Capital raised <strong>Uniti Group Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNIT#NASDAQ">UNIT</a>) price target from $5.5 to $6. RBC Capital analyst Bora Lee maintained a Sector Perform rating. Uniti shares closed at $5.70 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Loop Capital increased <strong>Datadog, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) price target from $160 to $200. Loop Capital analyst Yun Kim maintained a Buy rating. Datadog shares closed at $149.46 on Friday.  <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel cut the price target for <strong>Schlumberger Limited</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) from $60 to $59. Stifel analyst Stephen Gengaro maintained a Buy rating. Schlumberger shares settled at $36.83 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays raised <strong>Carnival Corporation</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) price target from $31 to $32. Barclays analyst Brandt Montour maintained an Overweight rating. Carnival shares closed at $26.80 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. increased <strong>SoundHound AI, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) price target from $8 to $26. HC Wainwright &amp; Co. analyst Scott Buck maintained a Buy rating. SoundHound AI shares closed at $21.75 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
<p><strong>Read This Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></strong></li>
</ul>


Price Target

Analyst Ratings

DDOG

HUMA

MSFT

SNOW

SOUN

UNIT

VRTX

Microsoft To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Monday

Direct Digital Shares Resume Trade Then Again Halted On Circuit Breaker To The Upside, Stock Now Up 210.9%

<p><strong>Xerox Holdings Corporation</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRX#NASDAQ">XRX</a>) shares are trading higher after the company disclosed a deal to acquire <strong>Lexmark International, Inc. </strong>from <strong>Ninestar Corporation</strong>, <strong>PAG Asia Capital</strong>, and <strong>Shanghai Shouda Investment Centre</strong> for<a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42643529/xerox-to-acquire-lexmark" rel="noreferrer noopener"> $1.5 billion, including assumed liabilities</a>.</p>
<p>This acquisition will enhance Xerox's core print portfolio and expand its global print and managed print services business.</p>
<p>The acquisition of Lexmark will integrate its solutions with Xerox ConnectKey technology and advanced Print and Digital Services, enhancing Xerox's offering portfolio and reinforcing its commitment to adding value for clients and partners.</p>
<p>It will also boost Xerox's ability to serve clients in the expanding A4 color market while diversifying its distribution and geographic footprint, particularly in the APAC region.</p>
<p><strong>Benefits &amp; Synergies</strong>: The combined entity will serve over 200,000 clients across 170 countries, with 125 manufacturing and distribution facilities in 16 countries.</p>
<p>The transaction will immediately lower Xerox's pro forma gross debt leverage ratio from 6.0x as of September 30, 2024, to around 5.4x before synergies.</p>
<p>After realizing $200 million in cost synergies, the ratio is expected to drop to approximately 4.4x. Xerox aims to reduce its gross debt leverage ratio to below 3.0x in the medium term.</p>
<p>The transaction is expected to be immediately accretive to both <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">earnings per share and free cash flow</a>.</p>
<p><strong>Dividend Cut</strong>: Xerox's Board of Directors approved a reduction in the annual dividend from $1 per share to 50 cents per share, starting with the dividend expected in the first quarter of 2025.</p>
<p>The company said this decrease in the dividend will free up additional funds for debt reduction while offering shareholders an above-market yield.</p>
<p>The Xerox Board has unanimously approved the transaction, which is subject to regulatory approvals, Ninestar's shareholder approval, and other customary closing conditions.</p>
<p>The deal is expected to close in the second half of 2025, with both Xerox and Lexmark continuing their operations independently until then.</p>
<p>Xerox held $521 million in cash and equivalents <a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41599453/xerox-clocks-7th-consecutive-revenue-miss-quarter-in-q3-slashes-2024-outlook-stock-tanks" rel="noreferrer noopener">as of September 30, 2024</a>.</p>
<p><strong>Price Action</strong>: XRX shares are up 7.27% at $9.01 at the last check on Monday.</p>
<p><strong>Read Next</strong>:</p>
<ul>
<li><strong><a href="https://www.benzinga.com//node/42647780" target="_blank" rel="noreferrer noopener">Despegar To Be Acquired By Prosus For $1.7 Billion in All Cash Deal</a></strong></li>
</ul>
<p><em>Photo by Mats Wiklund via Shutterstock</em></p>


Equities

Large Cap

Guidance

Movers

Xerox to Expand Global Print Business with $1.5 Billion Lexmark Buyout

<p>Shares of <strong>General Motors Company </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) are little changed Monday despite news that rivals <strong>Honda Motor Co., Ltd. </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMC#NYSE">HMC</a>) and <strong>Nissan Motor Co., Ltd. </strong>(OTC:<a class="ticker" href="https://www.benzinga.com/stock/NSANY#OTC">NSANY</a>) <a href="https://www.benzinga.com/24/12/42642773/honda-nissan-start-merger-talks">are discussing a merger</a>. </p>
<p>This would create the world's third-largest automaker.</p>
<p>It is not clear how this would affect the long-term prospects of GM. But in the short term, the recent downtrend may be over. The stage may be set for a rally. This is why we have made it our <a href="https://www.benzinga.com/topic/stock-of-the-day">Stock of the Day</a>.</p>
<p>Some analysts believe that markets are efficient and stocks follow a ‘random walk'. They are wrong. If the markets were random, all price levels would have equal importance. Clearly, that's not the case in the markets.</p>
<p>As you can see on the chart below, the $50.00 level has been important for GM since August. It was well-defined resistance and now it has converted into a support level.</p>
<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="562" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23105205/15-1-1024x562.png" alt="" class="wp-image-704471" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23105205/15-1-1024x562.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23105205/15-1-300x165.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23105205/15-1-768x421.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23105205/15-1.png 1489w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p>From a traditional fundamental analysis point of view, there is no reason why a stock should turn when it reaches a round level like GM did. But from a technical analysis perspective, the reason why is clear. It is because of investor and trader psychology.</p>
<p><strong>Read Also:</strong> <a href="https://www.benzinga.com/24/12/42553394/chargepoint-inks-pact-with-general-motors-eyes-installing-ultra-fast-charging-ports-at-key-locations"><strong>ChargePoint Inks Pact With General Motors &#8211; Eyes Installing Ultra-fast Charging Ports At Key Locations</strong></a></p>
<p>People like to place orders at nice round levels, and that is what happened here.</p>
<p>In addition, there is support at the $50.00 level because it had been resistance. In the financial markets support forming at levels that were previously resistance is a common occurrence. It also is because of investor and trader psychology.</p>
<p>It is due to ‘seller's remorse'.</p>
<p>When the $50.00 resistance was broken and the price moved higher, a number of the people who sold shares at the resistance decided that the decision to sell was a mistake. Some vowed to buy their shares back if they can do so at the same price they were sold at.</p>
<p>As a result, when the stock fell back to $50.00, they placed buy orders. The large concentration of these orders formed support.</p>
<p>Some of these buyers may become concerned others will be willing to pay higher prices and they know this is who the sellers will go to. So, they may increase the prices they are willing to pay. Others will see this and may do the same.</p>
<p>It could result in a bidding war or snowball effect that forces GM into a new uptrend.</p>
<p><strong>Read Next:</strong> </p>
<ul>
<li><a href="https://www.benzinga.com/24/12/42647650/palantir-vs-lockheed-a-tech-fueled-showdown-in-the-850-billion-defense-market">Palantir Vs. Lockheed: A Tech-Fueled Showdown In The $850 Billion Defense Market</a></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Technicals

NSANY

Stock Of The Day: Is The General Motors Downtrend Over?

<p><strong>News Corporation</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWS#NASDAQ">NWS</a>) shares are trading higher on Monday. On Sunday, the company inked a deal to sell its Foxtel Group to <strong>DAZN Group Limited </strong>for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42639259/news-corp-announces-agreement-to-sell-foxtel-to-dazn-for-enterprise-value-of-a-3-4-billion" rel="noreferrer noopener">an enterprise value</a> of roughly $2.12 billion (AU$3.4 billion).</p>
<p>As part of the deal, News Corp&#8217;s shareholder loans of AU$ 578 million will be fully repaid in cash at closing.</p>
<p>Foxtel&#8217;s debt will be refinanced and transferred, with News Corp retaining a 6% equity stake in DAZN and a seat on its Board of Directors.</p>
<p><strong>Telstra Group Ltd </strong>will also sell its minority stake in Foxtel, receive repayment of A$128 million in shareholder loans, and acquire a 3% equity interest in DAZN.7x its fiscal 2024 EBITDA.</p>
<p>The sale of Foxtel follows a strategic and financial review by News Corp as part of its efforts to optimize its portfolio and simplify its structure.</p>
<p>The deal with DAZN, known for its global reach, technology, and extensive content, will further strengthen Foxtel&#8217;s position as a digital-first, streaming-focused company, with Patrick Delany continuing as CEO.</p>
<p>This transaction allows News Corp to sharpen its focus on key growth areas: Dow Jones, Digital Real Estate Services, and Book Publishing.</p>
<p>Additionally, News Corp will maintain a stake in DAZN, a rapidly growing global sports streaming platform with over 300 million viewers across 200 markets.</p>
<p>The transaction is expected to close in the second half of fiscal 2025, subject to regulatory approvals and other customary conditions.</p>
<p>From a financial reporting perspective, Foxtel will be classified as discontinued operations starting in the second quarter of FY25.</p>
<p>News Corp Chief Executive Robert Thomson said, &#8220;Foxtel has been transformed into a genuine digital and streaming leader in Australia, and we believe DAZN is the right owner to take the business to the next level with their technological capabilities, global footprint and compelling sports rights.</p>
<p>&#8221;This transaction also allows News Corp to focus on our other growth pillars of Dow Jones, Digital Real Estate and Book Publishing, while benefiting from repayment of our shareholder loans and an improved credit profile.&#8221;</p>
<p>Shay Segev, DAZN&#8217;s Chief Executive Officer, added, &#8220;Australians watch more sport than any other country in the world, which makes this deal an incredibly exciting opportunity for DAZN to enter a key market, marking another step in our long-term strategy to become the global home of sport.&#8221;</p>
<p>As of September 30, NWS&#8217;s cash and cash <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41824310/news-corporation-reports-first-quarter-results-for-fiscal-2025" rel="noreferrer noopener">equivalents stood at $1.78 billion</a>.</p>
<p>Investors can gain exposure to the stock via <strong>ETF Opportunities Trust Tuttle Capital Shareholders First Index ETF</strong> (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ESGX#BATS">ESGX</a>).</p>
<p><strong>Price Action</strong>: NWS shares are up 0.36% at $30.81 at the last check on Monday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/general/entertainment/24/12/42401401/murdoch-succession-plan-faces-setback-as-commissioner-rejects-eldest-sons-control" target="_blank" rel="noreferrer noopener">Murdoch Succession Plan Faces Setback As Commissioner Rejects Eldest Son&#8217;s Control</a></strong></li>
</ul>


ETF Opportunities Trust Tuttle Capital Shareholders First Index ETF

ESGX

News Corp Sells Foxtel to DAZN for $2.12 Billion, Retains Stake in Global Sports Streaming

<p>Deep-pocketed investors have adopted a bullish approach towards Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in TTD usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 20 extraordinary options activities for Trade Desk. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 60% leaning bullish and 30% bearish. Among these notable options, 16 are puts, totaling $802,286, and 4 are calls, amounting to $156,510.</p>
<h3>What's The Price Target?</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $110.0 to $170.0 for Trade Desk during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In terms of liquidity and interest, the mean open interest for Trade Desk options trades today is 493.67 with a total volume of 5,958.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Trade Desk's big money trades within a strike price range of $110.0 to $170.0 over the last 30 days.</p>
<h3>Trade Desk 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734968728_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>TTD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$8.0</td>
<td>$7.8</td>
<td>$7.8</td>
<td>$120.00</td>
<td>$155.2K</td>
<td align="right">55</td>
<td align="right">0</td>
</tr>
<tr>
<td>TTD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/24/25</td>
<td>$5.2</td>
<td>$4.5</td>
<td>$4.5</td>
<td>$120.00</td>
<td>$67.5K</td>
<td align="right">99</td>
<td align="right">150</td>
</tr>
<tr>
<td>TTD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$4.35</td>
<td>$4.05</td>
<td>$4.35</td>
<td>$110.00</td>
<td>$65.2K</td>
<td align="right">59</td>
<td align="right">161</td>
</tr>
<tr>
<td>TTD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$8.6</td>
<td>$8.5</td>
<td>$8.5</td>
<td>$120.00</td>
<td>$63.7K</td>
<td align="right">55</td>
<td align="right">312</td>
</tr>
<tr>
<td>TTD</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$4.8</td>
<td>$4.6</td>
<td>$4.7</td>
<td>$110.00</td>
<td>$47.0K</td>
<td align="right">59</td>
<td align="right">423</td>
</tr>
</tbody>
</table>
</p>
<h3>About Trade Desk</h3>
<p>The Trade Desk provides a self-service platform that helps advertisers and ad agencies programmatically find and purchase digital ad inventory (display, video, audio, and social) on different devices like computers, smartphones, and connected TVs. It utilizes data to optimize the performance of ad impressions purchased. The firm's platform is referred to as a demand-side platform in the digital ad industry. The firm generates its revenue from fees based on a percentage of what its clients spend on advertising.</p>
<p>In light of the recent options history for Trade Desk, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Where Is Trade Desk Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 528,990, with TTD's price down by -2.3%, positioned at $122.14.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 52 days.</li>
</ul>
<h3>What The Experts Say On Trade Desk</h3>
<p>In the last month, 4 experts released ratings on this stock with an average target price of $139.5.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Wedbush has revised its rating downward to Outperform, adjusting the price target to $135.<br />
&#x2A; In a cautious move, an analyst from Scotiabank downgraded its rating to Sector Outperform, setting a price target of $133.<br />
&#x2A; An analyst from Truist Securities persists with their Buy rating on Trade Desk, maintaining a target price of $155.<br />
&#x2A; An analyst from Wedbush downgraded its action to Outperform with a price target of $135. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Trade Desk, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Trade Desk's Options Frenzy: What You Need to Know

<p>Investors with significant funds have taken a bullish position in TransMedics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>), a development that retail traders should be aware of.</p>
<p>This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga. The exact nature of these investors remains a mystery, but such a major move in TMDX usually indicates foreknowledge of upcoming events.</p>
<p>Today, Benzinga's options scanner identified 9 options transactions for TransMedics Gr. This is an unusual occurrence. The sentiment among these large-scale traders is mixed, with 33% being bullish and 33% bearish. Of all the options we discovered, 8 are puts, valued at $933,494, and there was a single call, worth $25,600.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $60.0 and $135.0 for TransMedics Gr, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in TransMedics Gr's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to TransMedics Gr's substantial trades, within a strike price spectrum from $60.0 to $135.0 over the preceding 30 days.</p>
<h3>TransMedics Gr 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734968723_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>TMDX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$78.0</td>
<td>$73.2</td>
<td>$75.0</td>
<td>$135.00</td>
<td>$300.0K</td>
<td align="right">2</td>
<td align="right">40</td>
</tr>
<tr>
<td>TMDX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$73.9</td>
<td>$73.8</td>
<td>$73.8</td>
<td>$135.00</td>
<td>$244.0K</td>
<td align="right">43</td>
<td align="right">33</td>
</tr>
<tr>
<td>TMDX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$32.5</td>
<td>$28.9</td>
<td>$28.91</td>
<td>$80.00</td>
<td>$144.5K</td>
<td align="right">141</td>
<td align="right">50</td>
</tr>
<tr>
<td>TMDX</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/19/25</td>
<td>$47.8</td>
<td>$43.6</td>
<td>$45.56</td>
<td>$100.00</td>
<td>$82.0K</td>
<td align="right">37</td>
<td align="right">18</td>
</tr>
<tr>
<td>TMDX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$20.0</td>
<td>$18.0</td>
<td>$20.0</td>
<td>$65.00</td>
<td>$80.0K</td>
<td align="right">89</td>
<td align="right">40</td>
</tr>
</tbody>
</table>
</p>
<h3>About TransMedics Gr</h3>
<p>TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.</p>
<h3>Present Market Standing of TransMedics Gr</h3>
<ul>
<li>With a trading volume of 288,303, the price of TMDX is up by 1.87%, reaching $62.85.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 63 days from now.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for TransMedics Gr with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


TMDX

Market Whales and Their Recent Bets on TMDX Options

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Nike</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with NKE, it often means somebody knows something is about to happen.</p>
<p>Today, Benzinga's options scanner spotted 13 options trades for Nike.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 46% bullish and 46%, bearish.</p>
<p>Out of all of the options we uncovered, 12 are puts, for a total amount of $626,297, and there was 1 call, for a total amount of $36,670.</p>
<h3>Predicted Price Range</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $70.0 to $100.0 for Nike during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Nike's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Nike's substantial trades, within a strike price spectrum from $70.0 to $100.0 over the preceding 30 days.</p>
<h3>Nike Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734968717_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$22.15</td>
<td>$21.8</td>
<td>$21.8</td>
<td>$100.00</td>
<td>$183.1K</td>
<td align="right">4</td>
<td align="right">84</td>
</tr>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$8.45</td>
<td>$8.25</td>
<td>$8.34</td>
<td>$85.00</td>
<td>$55.8K</td>
<td align="right">477</td>
<td align="right">204</td>
</tr>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$8.45</td>
<td>$8.3</td>
<td>$8.3</td>
<td>$85.00</td>
<td>$55.6K</td>
<td align="right">477</td>
<td align="right">271</td>
</tr>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$6.5</td>
<td>$6.25</td>
<td>$6.25</td>
<td>$82.50</td>
<td>$55.0K</td>
<td align="right">324</td>
<td align="right">176</td>
</tr>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$18.25</td>
<td>$17.65</td>
<td>$18.17</td>
<td>$95.00</td>
<td>$50.8K</td>
<td align="right">20</td>
<td align="right">29</td>
</tr>
</tbody>
</table>
</p>
<h3>About Nike</h3>
<p>Nike is the largest athletic footwear and apparel brand in the world. Key categories include basketball, running, and football (soccer). Footwear generates about two thirds of its sales. Its brands include Nike, Jordan (premium athletic footwear and clothing), and Converse (casual footwear). Nike sells products worldwide through company-owned stores, franchised stores, and third-party retailers. The firm also operates e-commerce platforms in more than 40 countries. Nearly all its production is outsourced to contract manufacturers in more than 30 countries. Nike was founded in 1964 and is based in Beaverton, Oregon.</p>
<p>Having examined the options trading patterns of Nike, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Current Position of Nike</h3>
<ul>
<li>Trading volume stands at 3,639,215, with NKE's price down by -0.08%, positioned at $76.88.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 87 days.</li>
</ul>
<h3>Professional Analyst Ratings for Nike</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $77.4.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Stifel keeps a Hold rating on Nike with a target price of $75.<br />
&#x2A; An analyst from Needham has revised its rating downward to Buy, adjusting the price target to $84.<br />
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Neutral rating for Nike, targeting a price of $73.<br />
&#x2A; An analyst from Deutsche Bank persists with their Buy rating on Nike, maintaining a target price of $82.<br />
&#x2A; An analyst from UBS has decided to maintain their Neutral rating on Nike, which currently sits at a price target of $73. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Nike with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Nike Unusual Options Activity

<p>Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.</p>
<ul>
<li>Jefferies analyst David Stanton downgraded the rating for <strong>Mesoblast Limited</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) from Buy to Hold. Mesoblast shares closed at $14.63 on Friday. <a href="https://www.benzinga.com/quote/MESO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>William Blair analyst Sami Corwin downgraded <strong>Applied Therapeutics, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLT#NASDAQ">APLT</a>) from Outperform to Market Perform. Applied Therapeutics shares closed at $0.8801 on Friday. <a href="https://www.benzinga.com/quote/APLT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BTIG analyst Thomas Catherwood downgraded the rating for <strong>Innovative Industrial Properties, Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIPR#NYSE">IIPR</a>) from Buy to Neutral. NCR Atleos shares closed at $73.66 on Friday. <a href="https://www.benzinga.com/quote/IIPR/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
<p>Considering buying MESO stock? Here&#8217;s what analysts think: </p>
<p><figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="590" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23104327/image-193-1024x590.png" alt="" class="wp-image-704457" style="width:578px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23104327/image-193-1024x590.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23104327/image-193-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23104327/image-193-768x442.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23104327/image-193.png 1085w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p><strong>Read This Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></strong></li>
</ul>


Downgrades

APLT

IIPR

MESO

This Mesoblast Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday

SoundHound AI Option Alert: Jan 3 $21 Calls Sweep (21) Near The Ask: 483 @ $2.401 Vs 834 OI; Ref=$20.83

<p>Shares of autonomous driving technology leader <strong>Pony AI Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) <a href="https://www.benzinga.com/24/11/42228142/symbotic-unusual-machines-vci-global-pony-ai-tesla-why-these-5-stocks-are-on-investors-radars-today">debuted on Nasdaq in November</a>.</p>
<p>The Fremont, California-based company has the largest fleet of Level 4 autonomous mobility, offering robotaxi and robotruck services across China, according to Goldman Sachs.</p>
<p><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/635ac86c2048c300015a37cd/allen-chang">Analyst <strong>Allen Chang</strong></a> initiated coverage of Pony AI with a Buy rating and a price target of $19.60.</p>
<p><strong>The </strong><strong>Pony AI</strong><strong> Thesis:</strong> The company is the first to operate completely driverless robotaxis in four tier-1 cities in China, having obtained regulatory permits for providing robotaxi services to the general public, Chang said in the initiation note.</p>
<p><strong>Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a></strong>.</p>
<p>While competition is a concern, it will take time for other companies to develop a vehicle that does not need any safety drivers to offer a better riding experience to passengers versus traditional taxis, the analyst stated. </p>
<p>"Besides, it also takes time to accumulate autonomous driving mileage / track record to earn the operation license from governments," he added.</p>
<p>"Pony AI continues to make progress on robotaxi commercialization, and we expect a revenue CAGR of 27% in 2024-27E on ramp up of its robotaxi fleet operation and start of licenses fee contribution from robotaxi solutions, then a 158% CAGR over 2027-30E with accelerated scale expansion, driving EBITDA and NI to turn positive in 2030E," Chang further wrote.</p>
<p><strong>Price Action:</strong> Shares of Pony AI had risen by 4.48% to $13.75 at the time of publication on Monday.</p>
<p><strong>Read More: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/24/11/42230178/chinas-robotaxi-firm-looks-to-diversify-supply-chain-as-nasdaq-debut-sees-disappointment-amid-global-competition-with-tesla-waymo-and-amazon">China&#8217;s Robotaxi Firm Pony AI Looks To Diversify Supply Chain After Nasdaq Debut, Growing Competition With Tesla, Waymo, And Amazon</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Analyst Color

Long Ideas

Initiation

PONY

Pony AI Speeds Past Competitors, Commercializes Fully Driverless Vehicles

<p>Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.</p>
<ul>
<li>Scotiabank analyst Sung Ji Nam initiated coverage on <strong>Thermo Fisher Scientific Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Sector Perform rating and announced a price target of $605. Thermo Fisher Scientific shares closed at $524.05 on Friday. <a href="https://www.benzinga.com/quote/TMO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs analyst Allen Chang initiated coverage on <strong>Pony AI Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) with a Buy rating and announced a price target of $19.6. Pony AI shares closed at $13.16 on Friday. See how other analysts view this stock.</li>
<li>Compass Point analyst Dominick Gabriele initiated coverage on <strong>NCR Atleos Corporation</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NATL#NYSE">NATL</a>) with a Buy rating and announced a price target of $57. NCR Atleos shares closed at $32.33 on Friday. <a href="https://www.benzinga.com/quote/NATL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>D. Boral Capital analyst Jason Kolbert initiated coverage on <strong>Omeros Corporation</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) with a Buy rating and announced a price target of $36. Omeros shares closed at $10.31 on Friday. <a href="https://www.benzinga.com/quote/OMER/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Alliance Global Partners analyst Aaron Grey initiated coverage on <strong>Worksport Ltd.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKSP#NASDAQ">WKSP</a>) with a Buy rating and announced a price target of $2. Worksport shares closed at $0.8465 on Thursday. <a href="https://www.benzinga.com/quote/WKSP/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
<p>Considering buying OMER stock? Here&#8217;s what analysts think: </p>
<p><figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="573" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23103558/image-192-1024x573.png" alt="" class="wp-image-704444" style="width:622px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23103558/image-192-1024x573.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23103558/image-192-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23103558/image-192-768x430.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23103558/image-192.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p><strong>Read This Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></strong></li>
</ul>


NATL

OMER

WKSP

This Omeros Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

RELI

Reliance Global Shares Resume Trade

Reliance Global Shares Halted On Circuit Breaker To The Upside, Stock Now Up 290.8%

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>One of the oldest maxims in investing is that higher risk produces greater returns. That maxim holds particularly true across penny <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks.</a> Developing therapeutics to cure diseases is a complex business model fraught with the potential to fail at many points.&nbsp;</p>



<p>Developmental and regulatory time frames are long, introducing multiple potential points of failure. The capital necessary for research and development is substantial. So on and so forth. The result is that many&nbsp;upstart biotech firms fail to commercialize, taking their equity down in the process.</p>



<p>Those firms that make it through and reach commercialization are rewarded with the spoils of success. They pay shareholders handsomely with returns that can turn a small investment into a fortune. The firms discussed below still have reasonable chances of commercialization and the potential to reward investors handsomely. Even if they don&rsquo;t ultimately reach success, they can still reward investors handsomely as they pass milestones in the development process.</p>



<h2>FibroGen (FGEN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/pte_biotech_1600-300x169.png" alt="Medical technology network team meeting concept. Doctor hand working smart phone modern digital tablet laptop computer graphics chart interface, sun flare effect photo, PTE"><div>Source: everything possible / Shutterstock.com</div></div><p><strong>FibroGen</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/fgen-stock-quote/"><strong>FGEN</strong></a></span>) continues on the path toward commercialization for multiple drugs, targeting multiple diseases. The firm&rsquo;s leading candidate drugs include Pamrevlumab, Roxadustat and several other oncology therapeutics.</p>



<p>Pamrevlumab is currently in Phase 3 clinical trials for the treatment of a certain form of pancreatic cancer. It is also concurrently being studied in phase 2/3&nbsp;clinical studies for metastatic pancreatic cancer. Roxadustat is a drug that induces the production of red blood cells and is approved in multiple countries for use in treating anemia in chronic kidney disease populations. A supplemental New Drug Application (sNDA) has been submitted in China for the drug. It has been accepted for review by the China Health Authority.&nbsp;</p>



<p>One of the more compelling aspects of FibroGen as an investment in financial performance. During the <a href="https://www.globenewswire.com/news-release/2024/05/06/2876129/33525/en/FibroGen-Reports-First-Quarter-2024-Financial-Results.html">first quarter, revenues</a> approached $56 million, up from $36 million a year earlier. The increased revenues allow the company to slash its net losses from $76.7 million to just below $32 million this quarter. Shares currently trade for $1.30 with a <a href="https://stockanalysis.com/stocks/fgen/forecast/">consensus target price of $5</a> and analyst targets ranging as high as $11.</p>



<h2>Nuvectis Pharma (NVCT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/biopharma-1600-300x169.jpg" alt="Illustration of a biopharma company. Doctor standing in front of various medical icons."><div>Source: Billion Photos / Shutterstock</div></div><p><strong>Nuvectis Pharma</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/nvct-stock-quote/"><strong>NVCT</strong></a></span>) is another oncology-oriented biotech stock. It&rsquo;s particularly interesting as a potential investment because while it is in the pre-revenue stages, it is also highly regarded and priced higher than one might expect.</p>



<p>Shares currently trade for $6.21, which is quite high for a pre-revenue biotech firm. Those shares have coverage from a single analyst who expects their value to rise to $22 in the future. Investors who look at the company&rsquo;s financial statements will see that it is basically treading water. NVCT has more than $19 million in liquidity and loses roughly $4 million a quarter on R&amp;D and administrative costs.&nbsp;</p>



<p>The reason for optimism surrounding Nuvectis Pharma is simple: Lead candidate drug <a href="https://www.globenewswire.com/news-release/2024/05/07/2876700/0/en/Nuvectis-Pharma-Inc-Reports-First-Quarter-2024-Financial-Results-and-Business-Highlights.html">NXP800 has been granted</a> fast-track designation by the FDA in platinum-resistant ARID1a-mutated ovarian cancer. It&rsquo;s currently in Phase 1b studies and has the potential to pass through multiple milestones moving forward that, if successful, will reward investors with strong and immediate returns.</p>



<h2>Relmada Therapeutics (RLMD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600-300x169.png" alt="OLK Stock. Modern Medical Research Laboratory: Two Scientists Wearing Face Masks use Microscope, Analyse Sample in Petri Dish, Talk. Advanced Scientific Lab for Medicine, Biotechnology. Blue Color. KZR stock. RSLS stock. Best Biotech Stocks to Buy"><div>Source: Gorodenkoff / Shutterstock.com</div></div><p><strong>Relmada Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/rlmd-stock-quote/"><strong>RLMD</strong></a></span>) is one of many promising late-stage biotech firms developing therapeutics to address diseases of the central nervous system. Those diseases include disorders with high unmet needs including major depressive disorder (MDD), a primary focus of the firm.</p>



<p>REL-1017 is one of the company&rsquo;s lead candidate drugs. The drug is in late-stage development for the treatment of MDD. It is being studied to understand the potential of the drug as a fast-acting, once-daily antidepressant treatment.&nbsp;It is currently being studied in two Phase 3 double placebo-controlled studies.</p>



<p>The company also acquired the rights to a psilocybin and derivatives program&nbsp;in 2021. That program has been rebranded as REL-P11 and is being studied for its efficacy in both neurogenesis and in ameliorating the effects of neurodegenerative conditions.&nbsp;</p>



<p>Psilocybin and other psychoactive drugs are currently a hot area of research. Although Ralmada Therapeutics is in the pre-revenue stages and shares trade for $3.04, the sole analyst with coverage believes those shares could be worth as much as $25 in the future.</p>



<h2>Anixa Biosciences (ANIX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600-1-300x169.jpg" alt="A scientist holds a test tube while it is in a container"><div>Source: Shutterstock</div></div><p><strong>Anixa Biosciences</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/anix-stock-quote/"><strong>ANIX</strong></a></span>) develops treatments and vaccines to address unmet needs in ovarian cancer and breast cancer. Shares currently trade for less than $3, while the single analyst with coverage believes the stock will <a href="https://www.pricetargets.com/NASDAQ/ANIX/">rise to $12 in value.</a>&nbsp;</p>



<p>The company very <a href="https://www.prnewswire.com/news-releases/anixa-biosciences-commences-treatment-of-fifth-patient-in-ovarian-cancer-car-t-clinical-trial-302150758.html">recently commenced treatment</a> on the 5th patient in an ovarian cancer CAR-T clinical trial. The company is enrolling patients in its first-in-human trial who were unresponsive to at least two prior therapies. Safety was confirmed in the first three-patient cohort. The company is tripling the dose in patients four and five in order to establish dosage tolerability.&nbsp;</p>



<p>The company also recently expanded its partnership with the Cleveland Clinic to develop cancer vaccines. That partnership aims to further the development of vaccines targeting rare and aggressive forms of breast and ovarian cancer. Anixa Biosciences will continue to be an interesting stock for investors, especially in light of strong positive news on multiple fronts.</p>



<h2>Genenta Science (GNTA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600-min-1-300x169.jpg" alt="an image of a microscope, NEXI stock"><div>Source: Shutterstock</div></div><p>Let&rsquo;s begin discussing<strong> Genenta Science</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/gnta-stock-quote/"><strong>GNTA</strong></a></span>) stock in relation to its safety as an investment overall. Readers have noticed that multiple recommendations above have only one analyst rating. I don&rsquo;t have to explain why that introduces a lot of risk overall. The thing I want to note about Genenta Science is that it has <a href="https://stockanalysis.com/stocks/gnta/forecast/">two target prices,</a> one at $15 and the other at $25. Thus, the consensus price is $20. Genenta Science shares trade at $3.30.</p>



<p>While the company is attractive for its raw return potential, I should also note that there are a lot of unknowns with this company. It is an Italian company and doesn&rsquo;t provide a lot in the way of information. It&rsquo;s a lot easier to find updates on domestic companies. The information we do have is a<a href="https://ir.genenta.com/static-files/db77523d-9bdf-47bd-8120-02eb11e0d7df"> financial report dating from the end of 2023.</a> It simply shows the company is not producing much in the way of revenues.</p>



<p>The stock offers so much potential because the company is developing a stem cell platform for the safe treatment of solid tumors. It has <a href="https://www.globenewswire.com/news-release/2024/02/08/2825783/0/en/Genenta-Demonstrated-Reprogramming-of-the-Tumor-Microenvironment-in-GBM-Patients-Paving-the-Way-for-Innovative-Treatments-of-Solid-Tumors.html">demonstrated the potential</a> to reprogram the cells of glioblastoma patients.&nbsp;</p>



<h2>Affimed (AFMD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/red-blood-cells-300x169.jpg" alt="3d rendering red blood cells in vein"><div>Source: Phonlamai Photo / Shutterstock.com</div></div><p><strong>Affimed</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/afmd-stock-quote/"><strong>AFMD</strong></a></span>) continues to develop therapeutics for the treatment of lymphoma, a grouping of blood cancers that originate in the lymphatic system.</p>



<p>The stock is interesting for a number of reasons both operational and developmental. The company reduced <a href="https://www.globenewswire.com/news-release/2024/03/28/2853795/0/en/Affimed-Reports-2023-Financial-Results-and-Operational-Progress.html">its workforce by 50% in 2023</a> in an effort to streamline operations.</p>



<p>AFMD is redirecting its resources to three lead candidate programs following the restructuring. That leads me to my next point: The company is doing well from a developmental perspective. Each of those three candidate programs progressed in 2023. Affimed awaits further data readouts from those programs in Q2 and expects dose escalation. That implies current safety and will be used to establish the upper tolerability for those respective programs.&nbsp;</p>



<p>As with any penny biotech stock, failure is a distinct possibility. However, Affimed is well regarded and benefits from a <a href="https://stockanalysis.com/stocks/afmd/forecast/">consensus target price of $32.</a> It currently trades for just over $4.&nbsp;</p>



<h2>Lipocine (LPCN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600d-300x169.jpg" alt="Image of two scientists in lab coats studying results in a lab. best biotech stocks to buy"><div>Source: Shutterstock</div></div><p><strong>Lipocine</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/lpcn-stock-quote/"><strong>LPCN</strong></a></span>) stock trades for $6.89 but is expected to rise to $33. Like so many other stocks on this list, Lipocine only has coverage from one analyst. That introduces risk to what is already a risky biotech stock. However, that&rsquo;s the game investors must be willing to play in the risk-fueled world of pharma stock&nbsp;investing.</p>



<p>As you may have guessed by the firm&rsquo;s name, Lipocine does work in the obesity management space. Candidate drug Lpcn2401 is currently in Phase 2 studies and is showing promise in reducing obesity in patients with at least one co-related morbidity.</p>



<p>However, the company is also developing treatments outside of the weight loss realm. Those programs span disease areas, including postpartum depression, cirrhosis, essential tremors and testosterone replacement therapy.&nbsp;</p>



<p>What&rsquo;s particularly good about the company is that it actually produced positive net income in the most recent quarter. Lipocine <a href="https://www.prnewswire.com/news-releases/lipocine-announces-financial-results-for-the-first-quarter-ended-march-31-2024-302140431.html">reported $3.5 million in net income</a> in the first quarter, reversing a $3.9 million net loss 12 months prior.</p>



<p><em><strong>On <a href="https://investorplace.com/stock-types/penny-stocks/">Penny Stocks</a> and Low-Volume Stocks</strong>: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.</em></p>



<p><em><strong>Read More</strong>: <a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/">Penny Stocks &mdash; How to Profit Without Getting Scammed</a></em></p>



<p><em>On the date of publication, Alex Sirois did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/"><em> Publishing Guidelines.</em></a></p>
<div><p>Alex Sirois is a freelance contributor to InvestorPlace whose personal stock investing style is focused on long-term, buy-and-hold, wealth-building stock picks. Having worked in several industries from e-commerce to translation to education and utilizing his MBA from George Washington University, he brings a diverse set of skills through which he filters his writing.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/05/7-penny-biotech-stocks-to-triple-your-investment/">7 Penny Biotech Stocks to Triple Your Investment</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

7 Penny Biotech Stocks to Triple Your Investment

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Anixa Biosciences</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/anix-stock-quote/"><strong>ANIX</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Anixa Biosciences reported earnings per share of -10 cents. This was above the analyst estimate for EPS of -11 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/06/anix-stock-earnings-anixa-biosciences-for-q2-of-2024/">ANIX Stock Earnings: Anixa Biosciences Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

ANIX Stock Earnings: Anixa Biosciences Beats EPS for Q2 2024

Anixa Biosciences authorizes $5M share buyback program

Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on Anixa Biosciences (ANIX – Research Report) and keeping the price target at $7.00. Y...

Buy Rating Affirmed for Anixa Biosciences Amid Promising Cancer Therapy Trials

Analyst Yi Chen of H.C. Wainwright reiterated a Buy rating on Anixa Biosciences (ANIX – Research Report), retaining the price target of $7.00. Yi C...

Buy Rating Affirmed for Anixa Biosciences Amid Promising CAR-T Therapy Trials and Stable Financials

Anixa Biosciences ( ($ANIX) ) has provided an announcement. Anixa Biosciences, in collaboration with Cleveland Clinic, unveiled promising results f...

Anixa Biosciences Reports Promising Phase 1 Vaccine Results

Anixa Biosciences (ANIX) announced that it has dosed its first patient in the third cohort in the ongoing Phase 1 clinical trial of its novel chime...

Anixa Biosciences initiates third cohort in CAR-T clinical trial

Anixa Biosciences (ANIX) announced that its Board of Directors has approved the purchase of Bitcoin as a treasury reserve asset. With Anixa's stron...

Anixa Biosciences board approves purchase of Bitcoin as treasury reserve asset

Anixa rises as board approves Bitcoin as a treasury reserve asset

Anixa Biosciences: Uncertainty In The Pipeline, Uncertainty In Their Financial Outlook

AFMD

ANIX

FGEN

GNTA

LPCN

NVCT

RLMD

Press Releases

Anixa Biosciences Announces Submission of Protocol Amendment for CAR-T Trial

Anixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical Development

Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences and Cleveland Clinic to Present Additional Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Small Cap

Anixa Biosciences to Present at the Sidoti Micro-Cap Virtual Conference on November 13 & 14, 2024

Anixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Comments

Anixa Biosciences

Anixa Biosciences (ANIX) Opciones

Anixa Biosciences (NASDAQ:ANIX) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL